Two studies in this issue report on interventions to detect serious general medical conditions among people with mental illness. Stanley D. Rosenberg, Ph.D., and colleagues conducted a randomized trial of the "STIRR" model to detect blood-borne infections. The trial tested the feasibility of the intervention, which incorporates Screening, Testing, Immunization, Risk reduction counseling, and treatment Referral, in an urban sample of clients with serious mental illness and a substance use disorder—a group with a markedly elevated risk of HIV and hepatitis infection. Although clients in the STIRR intervention were more likely to be tested and immunized and to increase their knowledge about hepatitis, they did not reduce risky behaviors, were no more likely to be referred to care, and showed no increase in HIV knowledge. The average per patient cost was $541 (see page 885). Between 2005 and 2008, Pfizer, Inc., funded voluntary health fairs that offered free cardiometabolic screening and same-day feedback to outpatients with mental illness at community clinics across the country. In this issue, Christoph U. Correll, M.D., and colleagues report findings for 10,084 patients at 219 sites. Results on several indicators raised concern for more than half of these patients: 52% had metabolic syndrome, 52% were obese, and 51% were hypertensive. Of the 1,359 fasting patients with metabolic syndrome, 60% were not receiving any treatment (see page 892).